Corvus Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
Corvus Pharmaceuticals, Inc. (CRVS), a Delaware corporation, filed this Current Report on Form 8-K on March 13, 2026. The filing reports the entry into a material definitive agreement regarding the sale of the company's common stock.
Key Financial Metrics and Transaction Details
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a capital raising mechanism:
- Agreement Type: Amended and Restated Open Market Sale Agreement (At-the-Market Offering).
- Counterparty: Jefferies LLC (acting as sales agent).
- Maximum Aggregate Offering Price: Up to $200,000,000.
- Commission: Up to 3.0% of the gross sales price per share.
- Shares Sold to Date: As of March 13, 2026, the Company had not sold any shares under the Original Sales Agreement (dated August 6, 2024) or the new Amended Sales Agreement.
Material Changes Versus Prior Period
The filing represents a material change in the Company's capital raising capacity:
- Capacity Increase: The maximum aggregate offering price was increased from $100,000,000 under the Original Sales Agreement to $200,000,000 under the Amended Sales Agreement.
- Amendment Status: The new agreement amends and restates the prior agreement; no shares were sold under the prior agreement prior to this amendment.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company has established a mechanism to sell shares from time to time through Jefferies. Jefferies is not required to sell any specific number or dollar amount of shares but will use commercially reasonable efforts consistent with normal sales practices.
Risks and Contingencies:
- Market Conditions: Sales are subject to market conditions and the discretion of the sales agent.
- Dilution: Future sales of common stock under this agreement will result in dilution to existing shareholders.
- Legal Compliance: The offering is subject to registration and qualification under applicable securities laws.
Key Facts for Investor Verification
- Verify the current share price and potential dilution impact of a $200 million offering.
- Confirm the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Review the full text of the Amended and Restated Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and covenants.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.